EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer: trial tests adding a pill to standard therapy
Disease control Not yet recruitingThis study is testing if adding a new oral drug, golidocitinib, to a standard chemotherapy and immunotherapy combination works better for people with newly diagnosed, advanced NK/T-cell lymphoma. It will compare the new three-drug combination against the standard two-drug combina…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug combo
Disease control Not yet recruitingThis study is testing whether adding a new immunotherapy drug called sugemalimab to standard chemotherapy works better than chemotherapy alone for adults with a rare and aggressive type of blood cancer (NK/T-cell lymphoma) that has returned or not responded to prior treatment. Th…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC